Compare Cassava Sciences Inc (FLNA) vs Victoria's Secret & Co (VSXY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Victoria's Secret & Co — how do they compare? Cassava Sciences Inc trades at $0.94 (market cap $47.75M), while Victoria's Secret & Co trades at $94.63 (market cap $7.48B). The key difference: Victoria's Secret & Co is far larger — about 156.6× Cassava Sciences Inc's market cap, and Victoria's Secret & Co is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals.
| FLNA | VSXY | |
|---|---|---|
Market Cap | $47.75M | $7.48B |
Sector | Health | Consumer Cyclical |
52-Week High | $4.64 | $99.97 |
52-Week Low | $0.87 | $21.34 |
Enterprise Value | -$34.93M | $10.13B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $0.9973, up 0.23% with a bearish technical signal despite recent earnings beats. The company shows negative profitability with ROE at -55.79% and ROA at -35.34%, though cash burn improved from -$33M to -$30M projected for 2026. Analyst consensus is strongly bullish with 8 buy ratings versus 4 hold ratings.
The outlook remains challenging due to persistent losses and negative cash flow, but analyst optimism and continued progress in TSC-related epilepsy therapies provide potential catalysts. Key risks include execution challenges in clinical development and the company's ability to secure additional funding.
Victoria's Secret (VSXY) trades at $99.97, up 1.45% today and near its 52-week high. The stock shows strong technical momentum with bullish moving averages and positive earnings surprises in three consecutive quarters. Revenue remains stable at $6.23B for 2025, while net income improved to $165M. Analyst consensus is bullish with 55.6% buy ratings and a $110 high price target, supported by recent international expansion success in China and Europe.
VSXY presents growth potential through international expansion and data-driven marketing, but faces valuation concerns with a P/E of 37.5 and competitive retail pressures. The stock's current price exceeds the consensus target, suggesting near-term consolidation risk despite positive technical momentum and improving fundamentals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Victoria's Secret & Co
Victoria's Secret & Co is a specialty retailer of lingerie, pajamas, and beauty products with prestige fragrances and body care. It serves customers at its Lingerie and Beauty stores around the globe and online enabling them to shop the brand anywhere and anytime.
Read more on VSXY →
